Clinical Trials Using HER2Bi-Armed Activated T Cells

Clinical trials are research studies that involve people. The clinical trials on this list are studying HER2Bi-Armed Activated T Cells. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Her2-BATs for the Treatment of Breast Cancer Leptomeningeal Metastases

    This phase I trial studies the best dose and side effects of Her2-BATs in treating patients with breast cancer that has spread to the meninges (the thin layers of tissue that cover and protect the brain and spinal cord) (leptomeningeal metastases). Her2-BATs is an anti-cancer agent created from patients own immune cells (T-cells) coated ('armed") with and experimental drug made up of bispecific antibodies called Herceptin and OKT3. The Her2-BATs antibody is able to react against human breast cancer. An antibody is a type of protein that helps protect the body from bacteria and disease. Her2-BATs works by seeking out certain cancer cells like on breast tumor cells that have a molecule called Her2 on their surface. The Her2-BATs antibody may target the Her2 receptor on the cancer cell and use the body's own immune system to destroy those cancer cells.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients with Metastatic Castration Resistant Prostate Cancer

    This phase II trial studies how well pembrolizumab and HER2Bi-armed activated T cells work in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. HER2Bi-armed activated T cells are made using T cells and may target and kill cancer cells. Giving pembrolizumab and HER2Bi-armed activated T cells may work better in treating patients with castration resistant prostate cancer.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan

  • A Specialized Type of Immune Cells (HER2Bi-Armed Activated T Cells) and Pembrolizumab in Treating Patients with Metastatic Breast Cancer

    This phase I / II trial studies the side effects and best dose of HER2Bi-armed activated T cells when given together with pembrolizumab in treating patients with breast cancer that has spread to other places in the body. HER2-BAT is an anti-cancer agent created from patient’s own immune cells (T cells) coated (“armed”) with an experimental drug made up of antibodies called Herceptin and OKT3. An antibody is a type of protein that helps protect the body from bacteria and diseases such as cancer. HER2-BATs may react against breast cancer by seeking out certain cancer cells that have a molecule called HER2, on their surface. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving HER2Bi-armed activated T cells and pembrolizumab may work better in treating patients with breast cancer.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia